Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06272994 · ClinicalTrials.gov registry record · NA
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 277
- Enrollment target
NCT06272994: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT06272994 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 277 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06272994, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 277 participants
- Enrollment target
Study Summary
This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.
Primary Outcome
The number of hours out of the seven days following enrollment in the trial that the patient is alive and not receiving vancomycin estimated using a proportional odds ratio model with the ordinal status levels being alive and not on vancomycin, alive and on vancomycin, or dead.
Interventions
- DIAGNOSTIC_TEST MRSA Nasal Swab PCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2025-02-27 |
| Phase | NA |
What the finished NCT06272994 record still lists
NCT06272994 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which MRSA Nasal Swab PCR is the first listed.
NCT06272994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06272994 about?
NCT06272994 is a clinical study titled "Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin". This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual...
What is the current status of trial NCT06272994?
This trial is currently completed. It is a NA study. The enrollment target is 277 participants. The study started on 2024-04-03. Estimated completion is 2025-02-27.
What interventions are being tested in trial NCT06272994?
The interventions under investigation include: MRSA Nasal Swab PCR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06272994?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06272994's enrollment target sits among peer trials
277 383rd of 2000 higher than 1,618 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI